Shanghai Registry of Acute Coronary Events

Shanghai Jiao Tong University School of Medicine

Status: Terminated

Conditions: Coronary Artery Disease; Acute Coronary Syndrome

Treatments: Drug: Tirofiban; Device: drug-eluting stent

Study type: Observational

Funder types: Other

Identifiers

NCT00713557

RJH

Details and patient eligibility

About

SRACE is an multicenter observational database of outcomes for patients who are hospitalized with an acute coronary events. SRACE includes over 20 hospitals in Shanghai China that have enrolled a total of more than 3,000 patients since 2005, with an annual enrollment of 500 patients. The major purpose of the SRACE program is to evaluate the prognosis of patients admitted to the hospital due to acute coronary events, comparing different therapeutic strategies, in-hospital transferring system, and so on. All participating physicians receive confidential quarterly reports showing ther outcomes side-by-side with the aggregate outcomes of all participating hospitals.

Full description

consecutive patients with STEMI who presented symptoms within 12 hours and treated by primary PCI in Shanghai, were enrolled in the prospective sysytem. Several strategies were applied in these patients, including physician vs. patient transfer strategy, upsteam vs. downstream strategy, Firebird stent vs. Excel stent (bio-absorbable SES), etc. Once the patient was randomized to one of these study, he will be denied to the others. Clinical and angiographic outcomes were compared, with the final purpose to find an optimal strategy in treating AMI patients.

Enrollment: 20,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients admitted to the hospital with acute coronary syndrome and received medical or interventional treatment

Exclusion criteria

• non ACS patients;
• complicated with other lethal disease
• predicted life span less than 12 months
• known allergy history to any anti-platelet or anti-thrombin medicine
• unconscious at the time of arrival at the hospital

Trial design

20,000 participants in 6 patient groups

1

Description:

patients with acute ST-elevation myocardial infarction and receiving primary percutaneous coronary intervention Subgroup: Patient Transferring vs. Physician Transferring strategy

Treatment:

Device: drug-eluting stent

2

Description:

patients with acute ST-elevation myocardial infarction treated by thrombolysis or facilitated PCI Subgroup: upstream use of Tirofiban + primary PCI vs. downstream use of tirofiban + primary PCI

Treatment:

Drug: Tirofiban

Device: drug-eluting stent

3

Description:

patients with non-ST-elevation ACS treated by immediate PCI

Treatment:

Device: drug-eluting stent

4

Description:

patients with non ST-elevation ACS treated by elective PCI

Treatment:

Device: drug-eluting stent

5

Description:

STEMI patient with multivessel disease, complete revascularization is planned to achieve during the index hospitalization.i.e.P-PCI for culprit lesion,combined with staged PCI for remaining diseased vessel.

6

Description:

STEMI patient with multivessel disease, complete revascularization is planned to achieve at 6 weeks after STEMI onset.i.e.P-PCI for culprit lesion during index hospitalization,combined with staged PCI for remaining diseased vessel at 6-week's follow-up(secondary hospitalization).